drugset / Trial / NCT06267729

Study of AZD0754 in Participants With Metastatic Prostate Cancer

NCT06267729

Phase 1/2 Recruiting 60 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.

Timeline

Start
2024-03-12
Primary completion
2026-11-24
Completion
2026-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD0754 Cell therapy Intravenous
Subject AZD2287 Diagnostic / imaging agent